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G-protein coupled receptors (GPCRs) constitute the largest family of membrane receptors,
with high potential for drug discovery. These receptors can be activated by a panel of
different ligands including ions, hormones, small molecules, and vasoactive peptides.
Among those, angiotensins [angiotensin II (AngII) and angiotensin 1–7] are the major
biologically active products of the classical and alternative renin-angiotensin system
(RAS). These peptides bind and activate three different subtypes of GPCRs, namely AT1,
AT2, and Mas receptors, to regulate cardiovascular functions. Over the past decade,
the contribution of several RAS components in tumorigenesis has emerged as a novel
important concept, AngII being considered as harmful and Ang1–7 as protective against
cancer. Development of selective ligands targeting each RAS receptor may provide novel
and efﬁcient targeted therapeutic strategies against cancer. In this review, we focus on
breast cancer to summarize current knowledge on angiotensin receptors (AT1, AT2, and
Mas), and discuss the potential use of angiotensin receptor agonists and antagonists in
clinics.
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The RAS is an endocrine system that plays a central role in car-
diovascular and renal physiology through regulation of blood
pressure and sodium balance. Deregulated RAS may contribute
to pathogenesis such as atherosclerosis, ischemic disease, hyper-
tension, and heart failure. The physiological effects of the RAS
are mediated by bioactive angiotensin peptides generated by enzy-
matic cascades and released in the systemic circulation as well as
locally in various tissues (Crowley and Coffman, 2012). The “clas-
sical RAS” produces the AngII octapeptide through cleavage of
inactive AngI by angiotensin converting enzyme (ACE), whereas
the “alternative RAS axis” (Santos et al., 2013) produces Ang1–
7 by subsequent cleavage of AngII by the ACE homolog ACE2
(Figure 1). All Angiotensin peptides bind to GPCRs, namely
AT1, and AT2 receptors for AngII and Mas receptor for Ang(1–
7), but activate distinct signaling pathways leading to different
and often opposite cellular effects (Figure 1). It is generally
accepted that the classical ACE/AngII/AT1 axis promotes most
of the RAS actions on cardiovascular, renal, and cerebral func-
tions, and that these effects are counteracted by activation of
the AT2 receptor (Porrello et al., 2009; McCarthy et al., 2013)
and by the “protective” ACE2/Ang(1–7)/Mas axis (Santos et al.,
2013).
Beyond cardiovascular functions, several studies have pointed
out a role for RAS components in solid tumors including breast
tumors (reviewed in George et al., 2010). Breast cancer is the
major cause of death by cancer in women worldwide and the
occurrence of distant metastasis is a critical event that limits
patients survival. While targeted molecular therapies have con-
siderably improved the management of primary breast tumors,
these remain poorly effective for the treatment of metastases. The
identiﬁcation of molecular agents that may contribute to breast
cancer progression is therefore essential for future development
of new therapeutic strategies. Targeting GPCRs is of particular
interest because of the availability of speciﬁc agonists and antag-
onists of the receptors. In addition, their cell surface location
makes them suitable for blockade by humanized antibodies, a
strategy successfully developed for HER2+ breast tumors with
trastuzumab (Herceptin®). Of interest, most components of the
RAS are locally expressed in breast tumors and microenvironment
(macrophages and vascular cells; Inwang et al., 1997; De Paepe
et al., 2001; Tahmasebi et al., 2006; Herr et al., 2008; George et al.,
2010) pointing out angiotensin receptors as potential targets in
breast cancer.
In this review,we summarize current knowledge on angiotensin
receptors (AT1, AT2, and Mas) in breast cancer, and discuss the
potential use of angiotensin receptor agonists and antagonists in
malignancy.
ANGIOTENSIN RECEPTORS IN CANCER
G-protein coupled receptors (GPCRs) of the renin-angiotensin
system (RAS) system are activated by angiotensin peptides which
are produced by angiotensin converting enzyme (ACE). ACE
inhibitors (ACEi) have been assessed in cancer to character-
ize angiotensin functions in tumor growth, angiogenesis, and
metastasis, and were shown to inhibit cell proliferation and
tumor progression in several cancer models (reviewed in Rosen-
thal and Gavras, 2009). However, ACEi prevent production
of both angiotensin II (AngII) and Ang1–7, thus prevent-
ing activation of all angiotensin receptors. Targeting speciﬁc
angiotensin receptors using selective agonists or antagonists
is warranted in order to validate their use to block tumor
progression.
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FIGURE 1 | Schematic representation of the classical and alternative
renin-angiotensin system (RAS) pathways. Available agonists and
antagonists are indicated for each angiotensin G-protein coupled receptor
(GPCR): AT1, AT2, and Mas. Available ARBs (AT1 receptor blockers) are
Losartan, Candesartan, Valsartan, Irbesartan, Telmisartan, Eprosartan,
Olmesartan, and Azilsartan.
AT1 RECEPTOR
The AT1 receptor is ubiquitously expressed in human tissues and
is responsible for most of the AngII actions. AT1 activation by
AngII triggers a large number of intracellular effectors leading
to modulation of various cell processes, including proliferation,
migration, angiogenesis, and inﬂammation, which are closely
associatedwith tumor progression (Deshayes andNahmias, 2005).
Angiotensin receptor blockers (ARBs), such as losartan, candesar-
tan, or valsartan, have been assayed both in cancer cells and
in mouse experimental models to characterize AngII/AT1 func-
tions in tumor growth, angiogenesis, and metastasis (George et al.,
2010). Evidence for a role of AT1 receptor on cancer cell metastasis
came from in vivo studies of lungmodels of metastasis. After injec-
tion of cancer cells into the tail vein of mice, oral administration of
candesartan led to a strong reduction of lungmetastasis (Miyajima
et al., 2002). However, in this study it was not clear whether ARBs
act on tumor cells or on the stromal microenvironment. The role
of AT1 in the tumor microenvironment has been investigated by
comparing the growth and vascularization of tumors injected sub-
cutaneously into wild type (WT) or AT1 knockout mice (Egami
et al., 2003; Fujita et al., 2005; Imai et al., 2007). Tumor growth and
vascularization were strongly reduced in AT1 null mice indicating
that the AT1 of host cells contributes to both tumor growth and
angiogenesis. Of interest, AT1-dependent tumor growth involves
an increase in VEGF synthesis, a well-known angiogenic factor
(Fujita et al., 2005). Furthermore, AT1 is highly expressed in the
stromal tissue surrounding the tumors, in particular in tumor-
associated macrophages (TAMs). Macrophage inﬁltration, as well
as levels of TAMs-released VEGF, were strongly reduced in AT1
null mice, supporting the hypothesis that host AT1 might also
participate in inﬂammation-related tumor angiogenesis to main-
tain tumor growth (Egami et al., 2003; Fujita et al., 2005). In
glial tumor patients, AT1 expression was associated with higher
proliferation and vascular density and with reduced survival,
indicating that AT1-expressing tumors are of poor prognosis
(Arrieta et al., 2008).
AT2 RECEPTOR
Angiotensin II also binds the AT2 receptor subtype but less is
known about the functional consequence of AT2 receptor acti-
vation in cancer. In vitro studies indicate that over expression of
AT2 reduces growth of lung adenocarcinomas cells (Pickel et al.,
2010). In agreement, exogenous administration of AT2 receptor
by nanoparticles was found to signiﬁcantly attenuate lung can-
cer growth in an orthotopic model of syngeneic tumor grafts
(Kawabata et al., 2012). AT2 receptor activation using the ago-
nist CGP42112A reduced colorectal liver metastasis (Ager et al.,
2010), suggesting that AT2 activation might provide a novel strat-
egy to inhibit tumor growth. Of interest, pancreatic cancer cells
subcutaneously injected in AT2 knockout mice grew signiﬁcantly
faster than in WT mice, indicating that AT2 receptors present
in the tumor microenvironment may prevent cancer progression
(Doi et al., 2010). However, in some other studies, the develop-
ment of chemically induced sarcomawas delayed in AT2 knockout
mice, andAT2 blockade byAT2 antagonist PD123319 signiﬁcantly
reduced lung carcinomas xenografts growth (Clere et al., 2010).
Thus, further studies are needed to elucidate AT2 functions in
cancer.
Studies on AT2 receptor signaling allowed the identiﬁcation
of several AT2 interacting partners that are related to can-
cer (Rodrigues-Ferreira et al., 2015). Among them, intracellular
proteins of the ATIP family are encoded by candidate tumor sup-
pressor gene MTUS1. MTUS1 was shown to be down regulated
in several solid tumors, including from pancreas (Seibold et al.,
2003), ovary (Pils et al., 2005), head-and-neck (Ye et al., 2007; Ding
et al., 2012), colon (Zuern et al., 2010), bladder (Xiao et al., 2012),
and breast (Rodrigues-Ferreira et al., 2009), and ATIPs have been
shown to display tumor suppressor effects (Seibold et al., 2003;
Rodrigues-Ferreira et al., 2009). Investigating the functional rela-
tionship between AT2 and ATIPs might bring more clues toward
understanding the effects of AT2 in cancer.
MAS RECEPTOR
Angiotensins 1–7, the cleavage product of AngII by ACE2, belongs
to the alternative RAS pathway and has protective effects on
cardiovascular functions (Santos et al., 2013). Ang1–7 is an anti-
proliferative and anti-angiogenicmolecule thatmediates its effects
by binding to a uniqueGPCR,Mas (Santos et al., 2003; Passos-Silva
et al., 2013).
The anti-proliferative and anti-angiogenic effects of the Ang1–
7/Mas axis in cancer have been evaluated. In vitro studies on lung
cancer cells conﬁrmed the anti-proliferative function of Ang1–7
throughMas receptor (Gallagher andTallant, 2004). In vivo studies
further indicated that administration of Ang1–7 reduces lung and
prostate tumor xenografts (Gallagher and Tallant, 2004; Menon
et al., 2007; Krishnan et al., 2013a), aswell as prostate cancermetas-
tasis (Krishnan et al., 2013b). Of interest, Ang1–7 effect on tumor
growth was associated with a strong effect on tumor microenvi-
ronment. Administration of Ang1–7 has been shown to act on
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endothelial cells to inhibit angiogenesis (Machado et al., 2001;
Soto-Pantoja et al., 2009) but also on cancer-associated ﬁbrob-
lasts and osteoclasts to reduce breast cancer ﬁbrosis and metastatic
prostate tumor osteoclastogenesis, respectively (Cook et al., 2010;
Krishnan et al., 2013b). All in vitro effects of Ang1–7 are inhib-
ited by the Mas receptor antagonist A779 (Machado et al., 2001),
suggesting that Mas receptor mediates all protective functions of
Ang1–7.
ANGIOTENSIN RECEPTORS IN BREAST CANCER
In breast tumors, most components of the RAS are expressed
(George et al., 2010), suggesting that AngII may be locally pro-
duced. Studies from our group aimed at investigating the effect
of AngII on breast cancer progression. To this end, metastatic
breast cancer cells (D3H2LN) were exposed to AngII in vitro
prior to injection into the blood ﬂow of immunodeﬁcient mice
(Rodrigues-Ferreira et al., 2012a). Our studies revealed for the
ﬁrst time that AngII can directly act on breast cancer cells to
promote cancer cell invasion and metastasis (Rodrigues-Ferreira
et al., 2012a). Two major pathways activated by AngII were identi-
ﬁed, that were related to cell proliferation and migration/invasion,
respectively. These data highlight the importance of deﬁning the
role of angiotensin receptors in breast cancer as a ﬁrst step toward
blocking AngII production using ACEi or speciﬁcally targeting
RAS GPCRs.
AT1
AT1 has been shown to be expressed both at mRNA and pro-
tein levels in normal and malignant breast tissues (De Paepe et al.,
2001; Tahmasebi et al., 2006; Herr et al., 2008; Table 1). Func-
tional studies indicated that over expression of AT1 in breast
cancer cells promotes cell invasion in vitro and tumor growth
in vivo in absence of any stimulation by the AT1 agonist AngII
(Rhodes et al., 2009). All these effects were dose-dependently
inhibited by the AT1 antagonist losartan conﬁrming the spe-
ciﬁc role of AT1. Blockade of AT1 by ARBs, such as losartan
or candesartan, was shown to inhibit breast cancer cell pro-
liferation in vitro and breast tumor xenograft growth in mice
(Chen et al., 2013), suggesting that AT1 may be an interesting
target against breast cancer. Interestingly, in vitro studies demon-
strated that AT1 levels are increased in tamoxifen-resistant MCF7
cells as compared to sensitive counterparts, and that tamox-
ifen sensitivity was restored by blockade of AT1 by losartan
(Namazi et al., 2014a,b).
A large-scale meta-analysis performed on 31 breast cancer pro-
ﬁling datasets has revealed over expression of the AT1 receptor
gene (AGTR1) in 10–20% of invasive breast tumors (Rhodes et al.,
2009), all of which were estrogen receptor positive (ER+) and
human epidermal receptor 2 (HER2)-negative. In another subset
of 178 HER2-negative breast tumor patients, high AT1 expres-
sion was identiﬁed as a marker of resistance to anthracyclin-based
neoadjuvant chemotherapy (de Ronde et al., 2013). Recent studies
further suggested that high AT1 level may be a predictive marker
of bevacizumab response in breast tumors (Sánchez-Rovira et al.,
2013; Salvador et al., 2014). Of interest, bevacizumab-induced
hypertension in breast cancer patientswas also associatedwith bet-
ter overall response to this anti-angiogenic therapy (Gampenrieder
et al., 2014).
AT2
AT2 receptor levels have been shown to be markedly increased in
breast tumors as compared to normal tissue (De Paepe et al., 2002;
Table 1) raising the question of the functional effect of AT2 over
expression in breast cancer. To speciﬁcally examine this question,
we generated a human metastatic breast cancer cell line stably
expressing high amounts of human AT2 receptors at the plasma
membrane and no detectable AT1 levels (Rodrigues-Ferreira et al.,
2012b). This model allows the characterization of AT2 functions
independently of those related to AT1 receptor activation, which
is of great interest in the context of AT1 blockade by ARBs. It also
offers a unique opportunity to evaluate the consequences of AT2
receptor activation and blockade on breast cancer proliferation,
invasion, and migration, as well as on tumor growth and metasta-
sis. Thismodel is also suitable to investigatewhetherAT2 functions
may rely on interaction with intracellular partners (Rodrigues-
Ferreira et al., 2015). ATIPs are interesting AT2 partners in the
Table 1 | Renin-angiotensin system (RAS) G-protein coupled receptors (GPCRs) in breast cancer.
Receptor Detection method In vivo model Observation Reference
AT1 IHC/ISH Increased in benign and malignant tumors De Paepe et al. (2001)
qPCR Increased in carcinomas Tahmasebi et al. (2006)
IHC expressed in both ER+ and ER− Herr et al. (2008)
FISH/qPCR overexpression in 10–20% breast carcinomas Rhodes et al. (2009)
MCF7 (subcutaneous) Candesartan reduced tumor growth Chen et al. (2013)
MCF7 (subcutaneous) Losartan reduced growth of AGTR1-overexpressing tumors Rhodes et al. (2009)
AT2 qPCR Increased in carcinomas Tahmasebi et al. (2006)
IHC/ISH Increased in benign and malignant tumors De Paepe et al. (2002)
MAS RT-PCR detected in normal and malignant samples Miller et al. (1997)
ZR75−1, BT474 (orthotopic) Ang1–7 reduces tumor growth Cook et al. (2010)
IHC: Immunohistochemistry; ISH: In situ hybridization, qPCR: quantitative PCR; FISH: Fluorescent in situ hybridization.
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context of cancer, as ATIP1 has been shown to reduce proliferation
of pancreatic cancer cells (Seibold et al., 2003) whereas ATIP3,
which is down-regulated in breast cancer, reduces tumor growth,
and metastasis in experimental mice models (Rodrigues-Ferreira
et al., 2009). However, whether the consequence of AT2-ATIPs
interaction is to promote or prevent breast cancer progression
remains to be elucidated.
MAS
By quantitative RT-PCR, Harmer et al. (2002) found ACE2
expressed in most human cell lines and tissues examined includ-
ing breast, indicating thatAng1–7 can be produced inmost tissues.
Preliminary studies detected Mas receptor at the mRNA level by
RT-PCR in both benign and malignant breast tissues (Miller et al.,
1997; Table 1). These results need to be validated at the protein
level but one can speculate thatMas/Ang1–7 axis is present and tar-
getable in breast tumors. Of interest, in orthotopic breast cancer
xenograft models, administration of Ang1–7 efﬁciently reduced
tumor volume and weight (Cook et al., 2010) by acting both on
tumor cells and microenvironment. Thus, Ang1–7 may be a useful
therapeutic component against breast cancer.
TARGETING ANGIOTENSIN RECEPTORS IN BREAST CANCER
Preclinical studies thus provide a rationale for the potential use of
either ARBs or Mas agonist to treat breast cancer patients. To go
further, Ang1–7 andARBs have been assessed in clinics to evaluate
pharmacokinetics in phase I/II trial, and association with breast
cancer risk, respectively.
AT1
Eight different ARBs (Losartan, Candesartan, Valsartan, Irbe-
sartan, Telmisartan, Eprosartan, Olmesartan, and Azilsartan;
Figure 1) are currently approved for the treatment of hypertension
(Bader et al., 2012) and thus safely used in patients without major
side effect, indicating that these ARBs may be reconsidered for the
treatment of others pathologies including breast cancer. Several
studies evaluated breast cancer risk in ARBs users. Although one
study indicated that ARBs are associated with a modest increased
risk of new cancer diagnosis (Sipahi et al., 2010), other groups
rather reported that ARBs do not inﬂuence the risk of developing
a cancer, including breast cancer (Li et al., 2003; Fryzek et al., 2006;
ARB Trialists Collaboration, 2011; Azoulay et al., 2012; Bhaskaran
et al., 2012; Li et al., 2013). Several studies showed that there is
no signiﬁcant association between the use of ARBs and overall
survival of breast cancer patients (Sipahi et al., 2010; Chae et al.,
2011; Cardwell et al., 2014). Other analyses indicated that ARBs
users with invasive breast cancer have a reduced risk of recurrence
(Chae et al., 2011, 2013; Mc Menamin et al., 2012), although in
one study ARBs were not associated with breast cancer recurrence
(Sørensen et al., 2012), an apparent discrepancy that may reﬂect
variations in AT1 levels among different breast cancer populations
examined.
AT2
Compound C21 is the only non-peptide orally active AT2 receptor
agonist tested in several preclinical models with broad potential
indication (Unger and Dahlöf, 2010). C21 has been shown to have
beneﬁcial effects on blood pressure, cardiac, and kidney functions
and inﬂammation (Steckelings et al., 2011; McCarthy et al., 2013),
and its effects in cancer still need to be investigated. Other AT2
ligands are under preclinical development (Bader et al., 2012). In
particular the AT2 agonist LP2 compound (Lanthio Pharma) is
under evaluation in heart and lung injury (Wagenaar et al., 2013).
AT2 antagonists such as PD123319 and its orally active derivative
EMA401 were also investigated. Of interest, the highly selective
AT2 antagonist EMA401 is under development as a novel neu-
ropathic pain therapeutic agent (Rice et al., 2014). Thus, tools to
either block or activate the AT2 receptor (Figure 1) are under
development but preclinical studies are still needed to elucidate
AT2 functions in cancer and to adequately target this receptor, in
particular in breast cancer.
MAS
Targeting Mas receptor is a promising therapeutic option. Ang1–7
was evaluated in phase I clinical study involving eighteen patients
with advanced solid tumors from colon, lung, pancreas, prostate,
and soft tissues (Petty et al., 2009). Onlymild toxicity was observed
for high doses of Ang1–7 administrated subcutaneously (Petty
et al., 2009). Of interest, in this study Ang1–7 treatment led to
clinical beneﬁt for four patients. In a phase I/II clinical study,
Ang1–7 was administered before and after chemotherapy in breast
cancer patients with no dose-limiting toxicity (Rodgers et al.,
2006). These clinical studies suggest that Ang1–7 may be used
in patients without major side effect. To go further, new tools
to target Mas receptor are under development. These include
orally active Ang1–7 derivatives and new Mas agonists such as
the peptidic compound CGEN-856 and the non-peptidic AVE-
0991 compound (Figure 1; Bader et al., 2012; Ferreira et al., 2012).
Of note, patents were developed for the use of Ang1–7 as anti-
cancer and chemopreventive agents able to prevent and reduce
cancer growth, including in breast cancer (Tallant et al., 2011;
Tallant and Gallagher, 2014).
CONCLUSION
Angiotensin GPCRs appear as good therapeutic targets expressed
at the cell surface and thus easily targetable with pharmacolog-
ical drugs or humanized blocking antibodies. ARBs are already
widely used to treat hypertension and may be safely used in
other therapeutic applications, such as breast cancer, in combi-
nation with standard treatments. Targeting angiotensin receptors
may be promising in several aspects, since beneﬁcial effects
of ARBs and Ang1–7 were observed on both tumor cells and
tumor microenvironment (Cook et al., 2010; Chen et al., 2013).
ARBs and Ang1–7 were also shown to reduce collagen secretion
and deposition (Cook et al., 2010; Diop-Frimpong et al., 2011),
enhancing drug delivery and potentiating chemotherapy (Diop-
Frimpong et al., 2011; Chauhan et al., 2013). These interesting
results open the way to the use of ARBs/Ang1–7 in comple-
ment with chemotherapy to improve their efﬁciency. Of note,
protective effects of ARBs in cancer may be potentiated by Mas
activation, as suggested in studies of vascular remodeling (Iwai
et al., 2012). In addition, ARBs have been shown to reduce car-
diotoxicity of anthracyclin-based chemotherapy of breast cancer
(Thakur andWitteles, 2014), whereas Ang(1–7) reduces cytopenia
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of ovarian cancer patients treated with gemcitabine/platinum-
based chemotherapy (Pham et al., 2013). Thus using ARBs or
Ang1–7 combined with chemotherapy may constitute an inter-
esting strategy to both increase drug efﬁciency and reduce its side
effects.
Future studies should be designed to further evaluate
angiotensin receptor levels in breast tumors, in an attempt to select
a population of patients that express high levels of AT1 or Mas
receptors and may thus beneﬁt from GPCR-targeted therapy.
ACKNOWLEDGMENTS
This work was supported by the Inserm, the Institut Gustave
Roussy, the association Odyssea and Proliﬁc.
REFERENCES
Ager, E. I., Chong, W. W., Wen, S. W., and Christophi, C. (2010). Targeting the
angiotensin II type 2 receptor (AT2R) in colorectal liver metastases. Cancer Cell
Int. 10, 19–30. doi: 10.1186/1475-2867-10-19
ARB Trialists Collaboration. (2011). Effects of telmisartan, irbesartan, valsartan,
candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
J. Hypertens. 29, 623–635. doi: 10.1097/HJH.0b013e328344a7de
Arrieta, O., Pineda-Olvera, B., Guevara-Salazar, P., Hernández-Pedro, N., Morales-
Espinosa, D., Cerón-Lizarraga, T. L., et al. (2008). Expression of AT1 and AT2
angiotensin receptors in astrocytomas is associated with poor prognosis. Br. J.
Cancer 99, 160–166. doi: 10.1038/sj.bjc.6604431
Azoulay, L., Assimes, T. L., Yin, H., Bartels, D. B., Schiffrin, E. L., and Suissa, S.
(2012). Long-term use of angiotensin receptor blockers and the risk of cancer.
PLoS ONE 7:e50893. doi: 10.1371/journal.pone.0050893
Bader, M., Santos, R. A., Unger, T., and Steckelings, U. M. (2012). New therapeutic
pathways in the RAS. J. Renin Angiotensin Aldosterone Syst. 13, 505–508. doi:
10.1177/1470320312466519
Bhaskaran,K.,Douglas, I., Evans, S., van Staa, T., and Smeeth, L. (2012). Angiotensin
receptor blockers and risk of cancer: cohort study among people receiving anti-
hypertensive drugs in UK General Practice Research Database. BMJ. 344, e2697.
doi: 10.1136/bmj.e2697
Cardwell, C. R., Mc Menamin, Ú. C., Hicks, B. M., Hughes, C., Cantwell,
M. M., Murray, L. J. (2014). Drugs affecting the renin-angiotensin system
and survival from cancer: a population based study of breast, colorectal,
and prostate cancer patient cohorts. BMC Med. 12:28. doi: 10.1186/1741-
7015-12-28
Chae, Y. K., Brown, E. N., Lei, X., Melhem-Bertrandt, A., Giordano, S. H., Litton,
J. K., et al. (2013). Use of ACE inhibitors and angiotensin receptor blockers and
primary breast cancer outcomes. J. Cancer 4, 549–556. doi: 10.7150/jca.6888
Chae, Y. K., Valsecchi, M. E., Kim, J., Bianchi, A. L., Khemasuwan, D.,
Desai, A., et al. (2011). Reduced risk of breast cancer recurrence in patients
using ACE inhibitors, ARBs, and/or statins. Cancer Invest. 29, 585–593. doi:
10.3109/07357907.2011.616252
Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., and Kozin,
S. V., et al. (2013). Angiotensin inhibition enhances drug delivery and poten-
tiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4,
2516. doi: 10.1038/ncomms3516
Chen, X., Meng, Q., Zhao, Y., Liu, M., Li, D., Yang, Y., et al. (2013). Angiotensin II
type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast
cancer. Cancer Lett. 328, 318–324. doi: 10.1016/j.canlet.2012.10.006
Clere, N., Corre, I., Faure, S., Guihot, A. L., Vessières, E., Chalopin, M., et al. (2010).
Deﬁciency or blockade of angiotensin II type 2 receptor delays tumorigenesis
by inhibiting malignant cell proliferation and angiogenesis. Int. J. Cancer 127,
2279–2291. doi: 10.1002/ijc.25234
Cook, K. L., Metheny-Barlow, L. J., Tallant, E. A., and Gallagher, P. E. (2010).
Angiotensin-(1-7) reduces ﬁbrosis in orthotopic breast tumors. Cancer Res. 70,
8319–8328. doi: 10.1158/0008-5472.CAN-10-1136
Crowley, S. D., and Coffman, T. M. (2012). Recent advances involv-
ing the renin-angiotensin system. Exp. Cell Res. 318, 1049–1056. doi:
10.1016/j.yexcr.2012.02.023
De Paepe, B., Verstraeten, V. L., De Potter, C. R., Vakaet, L. A., and Bullock, G. R. .
(2001). Growth stimulatory angiotensin II type-1 receptor is upregulated in breast
hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem. Cell
Biol. 116, 247–254. doi: 10.1007/s004180100313
DePaepe, B.,Verstraeten,V.M.,De Potter, C. R., andBullock,G. R. (2002). Increased
angiotensin II type-2 receptor density in hyperplasia, DCIS, and invasive carci-
noma of the breast is paralleled with increased iNOS expression. Histochem. Cell
Biol. 117, 13–19. doi: 10.1007/s00418-001-0356-0
de Ronde, J. J., Lips, E. H., Mulder, L., Vincent, A. D., Wesseling, J., Nieuwland, M.,
et al. (2013). SERPINA6, BEX1,AGTR1, SLC26A3, and LAPTM4B are markers of
resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast
Cancer Res. Treat. 137, 213–223. doi: 10.1007/s10549-012-2340-x
Deshayes, F., and Nahmias, C. (2005). Angiotensin II receptors: a new role
in cancer? Trends Endocrinol. Metab. 16, 293–299. doi: 10.1016/j.tem.200
5.07.009
Ding,X., Zhang,N., Cai,Y., Li, S., Zheng,C., Jin,Y., et al. (2012). Down-regulation of
tumor suppressor MTUS1/ATIP is associated with enhanced proliferation, poor
differentiation, and poor prognosis in oral tongue squamous cell carcinoma. Mol.
Oncol. 6, 73–80. doi: 10.1016/j.molonc.2011.11.002
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., and Jain, R. K. (2011).
Losartan inhibits collagen I synthesis and improves the distribution and efﬁcacy
of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. U.S.A. 108, 2909–2914. doi:
10.1073/pnas.1018892108
Doi, C., Egashira, N., Kawabata, A., Maurya, D. K., Ohta, N., Uppalapati, D., et al.
(2010). Angiotensin II type 2 receptor signaling signiﬁcantly attenuates growth of
murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer 10:67. doi:
10.1186/1471-2407-10-67
Egami, K., Murohara, T., Shimada, T., Sasaki, K., Shintani, S., Sugaya, T., et al.
(2003). Role of host angiotensin II type 1 receptor in tumor angiogenesis and
growth. J. Clin. Invest. 112, 67–75. doi: 10.1172/JCI16645
Ferreira, A. J., Bader, M., and Santos, R. A. (2012). Therapeutic targeting of the
angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-
angiotensin system: a patent review. Expert Opin. Ther. Pat. 22, 567–574. doi:
10.1517/13543776.2012.682572
Fryzek, J. P., Poulsen, A. H., Lipworth, L., Pedersen, L., Nørgaard, M., McLaugh-
lin, J. K., et al. (2006). A cohort study of antihypertensive medication use and
breast cancer among Danish women. Breast Cancer Res. Treat. 97, 231–236. doi:
10.1007/s10549-005-9091-x
Fujita, M., Hayashi, I., Yamashina, S., Fukamizu, A., Itoman, M., and Majima, M.
(2005). Angiotensin type 1a receptor signaling-dependent induction of vascular
endothelial growth factor in stroma is relevant to tumor-associated angiogenesis
and tumor growth. Carcinogenesis 26, 271–279. doi: 10.1093/carcin/bgh324
Gallagher, P. E., and Tallant, E. A. (2004). Inhibition of human lung can-
cer cell growth by angiotensin-(1-7). Carcinogenesis 25, 2045–2052. doi:
10.1093/carcin/bgh236
Gampenrieder, S. P., Romeder, F., Muß, C., Pircher, M., Ressler, S., Rinnerthaler, G.,
et al. (2014). Hypertension as a predictive marker for bevacizumab in metastatic
breast cancer: results from a retrospective matched-pair analysis. Anticancer. Res.
34, 227–233.
George, A. J., Thomas, W. G., and Hannan, R. D. (2010). The renin-angiotensin
system and cancer: old dog, new tricks. Nat. Rev. Cancer 10, 745–759. doi:
10.1038/nrc2945
Harmer, D., Gilbert, M., Borman, R., and Clark, K. L. (2002). Quantitative mRNA
expression proﬁling of ACE 2, a novel homologe of angiotensin converting
enzyme. FEBS Lett. 532, 107–110. doi: 10.1016/S0014-5793(02)03640-2
Herr, D., Rodewald, M., Fraser, H. M., Hack, G., Konrad, R., Kreienberg, R.,
et al. (2008). Potential role of Renin-Angiotensin-system for tumor angiogen-
esis in receptor negative breast cancer. Gynecol. Oncol. 109, 418–425. doi:
10.1016/j.ygyno.2008.02.019
Imai, N., Hashimoto, T., Kihara, M., Yoshida, S., Kawana, I., Yazawa, T., et al.
(2007). Roles for host and tumor angiotensin II type 1 receptor in tumor
growth and tumor-associated angiogenesis. Lab. Invest. 87, 189–198. doi:
10.1038/labinvest.3700504
Inwang, E. R., Puddefoot, J. R., Brown, C. L., Goode, A. W., Marsigliante, S., Ho,
M. M., et al. (1997). Angiotensin II type 1 receptor expression in human breast
tissues. Br. J. Cancer 75, 1279–1283. doi: 10.1038/bjc.1997.217
Iwai, M., Nakaoka, H., Senba, I., Kanno, H., Moritani, T., and Horiuchi, M.
(2012). Possible involvement of angiotensin-converting enzyme 2 and Mas acti-
vation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular
remodeling. Hypertension 60, 137–144. doi: 10.1161/HYPERTENSIONAHA.112.
191452
www.frontiersin.org February 2015 | Volume 6 | Article 24 | 5
Rodrigues-Ferreira and Nahmias Angiotensin receptors in breast cancer
Kawabata, A., Baoum, A., Ohta, N., Jacquez, S., Seo, G. M., Berkland, C., et al.
(2012). Intratracheal administration of a nanoparticle-based therapy with the
angiotensin II type 2 receptor gene attenuates lung cancer growth. Cancer Res. 72,
2057–2067. doi: 10.1158/0008-5472.CAN-11-3634
Krishnan, B., Torti, F. M., Gallagher, P. E., and Tallant, E. A. (2013a). Angiotensin-
(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts
with a decrease in angiogenic factors and an increase in sFlt-1. Prostate 73, 60–70.
doi: 10.1002/pros.22540
Krishnan, B., Smith, T. L., Dubey, P., Zapadka, M. E., Torti, F. M., Willingham,
M. C., et al. (2013b). Angiotensin-(1-7) attenuates metastatic prostate cancer and
reduces osteoclastogenesis. Prostate 73, 71–82. doi: 10.1002/pros.22542
Li, C. I., Daling, J. R., Tang, M. T., Haugen, K. L., Porter, P. L., Mal-
one, K. E. (2013). Use of antihypertensive medications and breast cancer risk
among women aged 55 to 74 years. JAMA Intern. Med. 173, 1629–1637. doi:
10.1001/jamainternmed.2013.9071
Li, C. I., Malone, K. E., Weiss, N. S., Boudreau, D. M., Cushing-Haugen, K. L., and
Daling, J. R. (2003). Relation between use of antihypertensive medications and
risk of breast carcinoma among women ages 65–79 years. Cancer 98, 1504–1513.
doi: 10.1002/cncr.11663
Machado, R. D., Santos, R. A., and Andrade, S. P. (2001). Mechanisms of
angiotensin-(1-7)-induced inhibition of angiogenesis. Am. J. Physiol. Regul.
Integr. Comp. Physiol. 280, R994–R1000.
McCarthy,C.A.,Widdop,R. E.,Denton,K.M., and Jones, E. S. (2013). Update on the
angiotensinAT(2) receptor. Curr. Hypertens. Rep. 15, 25–30. doi: 10.1007/s11906-
012-0321-4
Mc Menamin, Ú. C., Murray, L. J., Cantwell, M. M., and Hughes, C. M. (2012).
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in
cancer progression and survival: a systematic review. Cancer Causes Control 23,
221–230. doi: 10.1007/s10552-011-9881-x
Menon, J., Soto-Pantoja, D. R., Callahan, M. F., Cline, J. M., Ferrario, C. M., Tallant,
E. A., et al. (2007). Angiotensin-(1-7) inhibits growth of human lung adenocarci-
noma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer
Res. 67, 2809–2815. doi: 10.1158/0008-5472.CAN-06-3614
Miller, N., McCann, A. H., O’Connell, D., Pedersen, I. S., Spiers, V., Gorey, T., et al.
(1997). The MAS proto-oncogene is imprinted in human breast tissue. Genomics
46, 509–512. doi: 10.1006/geno.1997.5063
Miyajima, A., Kosaka, T., Asano, T., Asano, T., Seta, K., Kawai, T., et al.
(2002). Angiotensin II type I antagonist prevents pulmonary metastasis of
murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 62,
4176–4179.
Namazi, S., Rostami-Yalmeh, J., Sahebi, E., Jaberipour, M., Razmkhah, M., and
Hosseini, A. (2014a). The role of captopril and losartan in prevention and
regression of tamoxifen-induced resistance of breast cancer cell line MCF-7: an
in vitro study. Biomed. Pharmacother. 68, 565–571. doi: 10.1016/j.biopha.201
4.05.004
Namazi, S., Sahebi, E., Rostami-Yalmeh, J., Jaberipour, M., Razmkhah, M., Hosseini,
A., et al. (2014b). Effect of angiotensin receptor blockade on prevention and
reversion of tamoxifen-resistant phenotype in MCF-7 cells. Tumour Biol. doi:
10.1007/s13277-014-2713-3 [Epub ahead of print].
Passos-Silva, D. G., Verano-Braga, T., and Santos, R. A. (2013). Angiotensin-
(1-7): beyond the cardio-renal actions. Clin. Sci. (Lond.). 124, 443–456. doi:
10.1042/CS20120461
Petty,W. J., Miller, A. A., McCoy, T. P., Gallagher, P. E., Tallant, E. A., and Torti, F. M.
(2009). Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous
antiangiogenic hormone. Clin. Cancer Res. 15, 7398–7404. doi: 10.1158/1078-
0432.CCR-09-1957
Pickel, L.,Matsuzuka, T., Doi, C.,Ayuzawa, R.,Maurya,D. K., Xie, S. X., et al. (2010).
Overexpression of angiotensin II type 2 receptor gene induces cell death in lung
adenocarcinoma cells. Cancer Biol. Ther. 9, 277–285. doi: 10.4161/cbt.9.4.10643
Pils, D., Horak, P., Gleiss, A., Sax, C., Fabjani, G., and Moebus,V. J., et al. (2005). Five
genes from chromosomal band 8p22 are signiﬁcantly down-regulated in ovarian
carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer
104, 2417–2429. doi: 10.1002/cncr.21538
Pham, H., Schwartz, B. M., Delmore, J. E., Reed, E., Cruickshank, S., Drum-
mond, L., et al. (2013). Pharmacodynamic stimulation of thrombogenesis by
angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and
platinum-based chemotherapy. Cancer Chemother. Pharmacol. 71, 965–972. doi:
10.1007/s00280-013-2089-x
Porrello, E. R., Delbridge, L. M., and Thomas, W. G. (2009). The angiotensin II
type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front. Biosci.
(Landmark Ed). 14:972. doi: 10.2741/3289
Rhodes, D. R., Ateeq, B., Cao, Q., Tomlins, S. A.,Mehra, R., Laxman, B., et al. (2009).
AGTR1 overexpression deﬁnes a subset of breast cancerand confers sensitivity to
losartan, an AGTR1 antagonist. Proc. Natl. Acad. Sci. U.S.A. 106, 10284–10289.
doi: 10.1073/pnas.0900351106
Rice, A. S., Dworkin, R. H., McCarthy, T. D., Anand, P., Bountra, C.,
McCloud, P. I., et al. (2014). EMA401, an orally administered highly
selective angiotensin II type 2 receptor antagonist, as a novel treatment
for postherpetic neuralgia: a randomised, double-blind, placebo-controlled
phase 2 clinical trial. Lancet 383, 1637–1647. doi: 10.1016/S0140-6736(13)
62337-5
Rodgers, K. E., Oliver, J., and diZerega, G. S. (2006). Phase I/II
dose escalation study of angiotensin 1-7 [A (1-7)] administered before
and after chemotherapy in patients with newly diagnosed breast can-
cer. Cancer Chemother. Pharmacol. 57, 559–568. doi: 10.1007/s00280-00
5-0078-4
Rodrigues-Ferreira, S., Abdelkarim, M., Dillenburg-Pilla, P., Luissint, A. C., di-
Tommaso, A., Deshayes, F., et al. (2012a). Angiotensin II facilitates breast cancer
cell migration and metastasis. PLoS ONE 7:e35667–e35674. doi: 10.1371/jour-
nal.pone.0035667
Rodrigues-Ferreira, S., Morel, M., Reis, R. I., Cormier, F., Baud, V., Costa-Neto,
C. M., et al. (2012b). A novel cellular model to study angiotensin ii at2 receptor
function in breast cancer cells. Int. J. Peptides 2012, 1–6. doi: 10.1155/2012/
745027
Rodrigues-Ferreira, S., Di Tommaso, A., Dimitrov, A., Cazaubon, S.,
Gruel, N., Colasson, H., et al. (2009). 8p22 MTUS1 gene product ATIP3
is a novel anti-mitotic protein underexpressed in invasive breast carci-
noma of poor prognosis. PLoS ONE 4:e7239. doi: 10.1371/journal.pone.00
07239
Rodrigues-Ferreira, S., Molina, A., Nehlig, A., Nahmias, C. (2015). “The AT2
receptor and interacting proteins ATIPs in cancer,” in The Protective Arm of
the Renin Angiotensin System (RAS): Functional Aspects and Therapeutic Impli-
cations, eds T. Unger, U. M. Steckelings, and R. A. Santos (Amsterdam: Elsevier
Press).
Rosenthal, T., and Gavras, I. (2009). Angiotensin inhibition and malig-
nancies: a review. J. Hum. Hypertens. 23, 623–635. doi: 10.1038/
jhh.2009.21
Salvador, J., Manso, L., de la Haba, J., Jaen, A., Ciruelos, E., de Villena, M. C., et al.
(2014). Final results of a phase II study of paclitaxel, bevacizumab, and gemc-
itabine as ﬁrst-line therapy for patients with HER2-negative metastatic breast
cancer. Clin. Transl. Oncol. doi: 10.1007/s10549-010-1002-0 [Epub ahead of
print].
Sánchez-Rovira, P., Seguí, M. A., Llombart, A., Aranda, E., Antón, A., Sánchez, A.,
et al. (2013). Bevacizumab plus preoperative chemotherapy in operable HER2
negative breast cancer: biomarkers and pathologic response. Clin. Transl. Oncol.
15, 810–817. doi: 10.1007/s12094-013-1006-4
Santos, R. A., Ferreira, A. J., Verano-Braga, T., and Bader, M. (2013).
Angiotensin-converting enzyme 2, Angiotensin-(1-7) and Mas: new players of
the Renin Angiotensin System. J. Endocrinol. 216, R1–R17. doi: 10.1530/JOE-
12-0341
Santos, R. A., Simoes e Silva, A. C., Maric, C., Silva, D. M., Machado, R. P., de
Buhr, I., et al. (2003). Angiotensin-(1-7) is an endogenous ligand for the G
protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100, 8258–8263.
doi: 10.1073/pnas.1432869100
Seibold, S., Rudroff, C., Weber, M., Galle, J., Wanner, C., and Marx, M. (2003).
Identiﬁcation of a new tumor suppressor gene located at chromosome 8p21.3–22.
FASEB J. 17, 1180–1182.
Sipahi, I., Debanne, S. M., Rowland, D. Y., Simon, D. I., and Fang, J. C. (2010).
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised
controlled trials. Lancet Oncol. 11, 627–636. doi: 10.1016/S1470-2045(10)
70106-6
Sørensen, G. V., Ganz, P. A., Cole, S. W., Pedersen, L. A., Sørensen, H. T., Cronin-
Fenton, D. P., et al. (2012). Use of β-blockers, angiotensin-converting enzyme
inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence:
a Danish nationwide prospective cohort study. J. Clin. Oncol. 31, 2265–2272. doi:
10.1200/JCO.2012.43.9190
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery February 2015 | Volume 6 | Article 24 | 6
Rodrigues-Ferreira and Nahmias Angiotensin receptors in breast cancer
Soto-Pantoja, D. R., Menon, J., Gallagher, P. E., and Tallant, E. A.
(2009). Angiotensin-(1-7) inhibits tumor angiogenesis in human lung
cancer xenografts with a reduction in vascular endothelial growth fac-
tor. Mol. Cancer Ther. 8, 1676–1683. doi: 10.1158/1535-7163.MCT-
09-0161
Steckelings, U. M., Larhed., M., Hallberg, A., Widdop, R. E., Jones, E. S., Wallinder,
C., et al. (2011). Non-peptide AT2-receptor agonists. Curr. Opin. Pharmacol. 11,
187–192. doi: 10.1016/j.coph.2010.11.002
Tahmasebi, M., Barker, S., Puddefoot, J. R., andVinson, G. P. (2006). Localisation of
renin-angiotensin system (RAS) components in breast. Br. J. Cancer 95, 67–74.
doi: 10.1038/sj.bjc.6603213
Tallant, E. A., and Gallagher, P. E. (2014). Angiotensin-(1-7) As a Chemoprevention
Agent. Patent number: 20140296143.
Tallant, E. A., Gallagher, P. E., and Ferrario, C. M. (2011). Angiotensin-(1-7) and
angiotensin-(1-7) agonists for inhibition of cancer cell growth. Patent number:
8034781. doi: 10.1111/j.1476-5381.2012.01905.x
Thakur, A., and Witteles, R. M. (2014). Cancer therapy-induced left ventricu-
lar dysfunction: interventions and prognosis. J. Card. Fail. 20, 155–158. doi:
10.1016/j.cardfail.2013.12.018
Unger, T., and Dahlöf, B. (2010). Compound 21, the ﬁrst orally active, selective
agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor
research and therapeutic potential. J. Renin Angiotensin Aldosterone Syst. 11, 75–
77. doi: 10.1177/1470320309347792
Wagenaar, G. T., Laghmani, el H., Fidder, M., Sengers, R. M., de Visser, Y. P.,
de Vries, L., et al. (2013). Agonists of MAS oncogene and angiotensin II type
2 receptors attenuate cardiopulmonary disease in rats withneonatal hyperoxia-
induced lung injury. Am. J. Physiol. Lung. Cell Mol. Physiol. 305, L341–L351. doi:
10.1152/ajplung.00360.2012
Xiao, J., Chen, J. X., Zhu, Y. P., Zhou, L. Y., Shu, Q. A., and Chen, L. W. (2012).
Reduced expression of MTUS1 mRNA is correlated with poor prognosis in
bladder cancer. Oncol. Lett. 4, 113–118.
Ye, H., Pungpravat, N., Huang, B. L., Muzio, L. L., Mariggiò, M. A., Chen, Z., et al.
(2007). Genomic assessments of the frequent loss of heterozygosity region on
8p21.3–8p22 in head andneck squamous cell carcinoma. CancerGenet. Cytogenet.
176, 100–106. doi: 10.1016/j.cancergencyto.2007.04.003
Zuern, C., Heimrich, J., Kaufmann, R., Richter, K. K., Settmacher, U., Wanner, C.,
et al. (2010) Down-regulation of MTUS1 in human colon tumors. Oncol. Rep.
23, 183–189.
Conflict of Interest Statement: The authors declare that the researchwas conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 19 December 2014; paper pending published: 20 January 2015; accepted: 30
January 2015; published online: 17 February 2015.
Citation: Rodrigues-Ferreira S and Nahmias C (2015) G-protein coupled receptors of
the renin-angiotensin system: new targets against breast cancer? Front. Pharmacol.
6:24. doi: 10.3389/fphar.2015.00024
This article was submitted to Experimental Pharmacology and Drug Discovery, a
section of the journal Frontiers in Pharmacology.
Copyright © 2015 Rodrigues-Ferreira and Nahmias. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org February 2015 | Volume 6 | Article 24 | 7
